scholarly journals 116TiP KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti–PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC)

2021 ◽  
Vol 32 ◽  
pp. S1425-S1426
Author(s):  
W.C.V. Lai ◽  
M-J. Ahn ◽  
T. Shentzer ◽  
D. Kowalski ◽  
B.C. Cho ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung ◽  
Phase Ib ◽  
Extensive Stage ◽  
Investigational Agents

scholarly journals Cost-Effectiveness In The Second-Line Treatment Of Non-Small Cell Lung Cancer (Nsclc) In The Us

2015 ◽  
Vol 18 (7) ◽  
pp. A457-A458 ◽  
Author(s):  
C Graham ◽  
H Knox ◽  
LM Hess ◽  
M Jen ◽  
G Cuyun Carter ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung ◽  
The Us

scholarly journals PCN67 Erlotinib as Second Line Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC): Economic Modeling (EM) results

2011 ◽  
Vol 14 (7) ◽  
pp. A446 ◽  
Author(s):  
E.A.V. Santos ◽  
C.T. Buschinelli ◽  
M. Ferracini ◽  
C. Pepe ◽  
M. Estanislao
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Economic Modeling ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung

scholarly journals Erlotinib (ERL) versus Pemetrexed (MTA) as Second-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC): Efficacy and Safety Data

2012 ◽  
Vol 23 ◽  
pp. ix438-ix439
Author(s):  
J. Zugazagoitia ◽  
J. Puente ◽  
S. Hernandez ◽  
J.L. Gonzalez-Larriba ◽  
J. Sanz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Safety Data ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Efficacy And Safety ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document